The MUC1(CT) antibody specifically targets the C-terminal cytoplasmic tail of the mucin 1 (MUC1) protein, a transmembrane glycoprotein overexpressed in numerous epithelial cancers. MUC1 consists of an extracellular α-subunit with a variable number of tandem repeats (VNTR) and a transmembrane β-subunit. Under normal conditions, MUC1 is involved in cell signaling, protection of epithelial surfaces, and immune modulation. However, in cancer, MUC1 is aberrantly overexpressed and undergoes hypoglycosylation, exposing its normally hidden epitopes and promoting oncogenic signaling. The C-terminal region plays a critical role in intracellular signaling by interacting with kinases (e.g., EGFR, Src) and transcription factors (e.g., β-catenin), driving tumor progression, metastasis, and therapy resistance.
MUC1(CT)-specific antibodies are vital tools in cancer research, enabling detection of MUC1 expression and localization via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies help elucidate MUC1’s role in tumorigenesis and its interactions with signaling pathways. Therapeutically, targeting MUC1(CT) holds promise for developing monoclonal antibodies, antibody-drug conjugates (ADCs), or small-molecule inhibitors to disrupt oncogenic signaling. Clinical studies explore MUC1(CT)-targeting agents in cancers such as breast, pancreatic, and ovarian carcinomas. Despite challenges like tumor heterogeneity, MUC1(CT) remains a key focus for precision oncology due to its cancer-specific expression and functional relevance.